

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

November 11, 2025

## **Strict Allocation Notice**

Dear Valued Customer,

Due to ongoing market shortages and supply constraints, several products are now under **strict allocation**. As a result, **no allocation requests or additional inventory will be approved** beyond existing allocations at this time.

This measure is necessary to ensure equitable distribution of limited supply.

DIN	Fresenius Kabi Product Code	MSD Product Code	McKesson Product Code	Product Description	Strict Nov. Allocation	Strict Dec. Allocations
NA	622010	1000848	201602	Fresenius Kabi's US-Authorized Acyclovir Injection, USP 500 mg per 10 mL	100% of historical demand 10 mL + 100% historical demand 20 mL	100% of historical demand 10 mL
02439379	ABH3111	1000667	124857	Ropivacaine Hydrochloride Injection, USP 2mg/mL, 200 mL Bag	100% of historical demand	100% of historical demand
02439387	ABA1823	1000666	124858	Ropivacaine Hydrochloride Injection, USP 5mg/mL, 10 mL Ampoule	125% of historical demand	125% of historical demand
02439409	ABA1846	1000665	124903	Ropivacaine Hydrochloride Injection, USP 10 mg/mL, 10 mL Ampoule	100% of historical 10 mL demand + 70% of historical 20 mL demand converted to 10 mL	125% of historical demand (no longer covering for 20mL)

We recognize the difficulties and inconvenience that you may encounter as a result of these measures, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le

Associate Director, IV Drugs joseph.le@fresenius-kabi.com

